Search results
Americans with HIV are living longer. Federal spending isn’t keeping up.
Louisiana Illuminator via Yahoo News· 6 days agoDECATUR, Ga. — Malcolm Reid recently marked the anniversary of his HIV diagnosis on Facebook....
Americans With HIV Are Living Longer. Federal Spending Isn’t Keeping Up.
Arizona Mirror via Yahoo News· 5 days agoMore than half of the people living with HIV in the U.S. are older than 50, challenging medical...
On Call: Anthony Fauci Tells All—Nearly—on Trump, COVID and Other Disasters
The Daily Beast via Yahoo News· 19 hours agoHe tackled AIDS, Ebola, Middle East Respiratory Syndrome and SARS, yet at the end of his run,...
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Investor's Business Daily· 3 days agoThe news is a boon for Gilead Sciences, which already sells its HIV drugs Descovy and Truvada as...
Gilead Flashes Bullish Sign After HIV Drug Proves 100% Effective
Investor's Business Daily· 3 days agoThe news is a boon for Gilead Sciences (GILD), which already sells its HIV drugs Descovy and Truvada...
Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.
Barrons.com· 3 days agoGilead said there were 39 HIV cases among the 2,136 women who took Descovy and 16 among the 1,068...
Gilead Shot Prevents All HIV Cases in Trial of African Women
Bloomberg via Yahoo Finance· 3 days ago(Bloomberg) -- Gilead Sciences Inc.’s experimental twice-yearly shot prevented 100% of HIV cases in...
Why this Wistar scientist sees hope for an HIV cure - Philadelphia Business Journal
The Business Journals· 7 days agoDr. Luis J. Montaner leads the HIV Research Program at The Wistar Institute’s Vaccine &...
Gilead’s long-acting HIV drug superior to daily pill Truvada in study
WSAU Wausau· 3 days ago(Reuters) - Gilead Sciences said on Thursday a late-stage study showed its injectable drug,...
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial By Proactive...
Investing.com· 3 days agoGilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm...